Legal & General Group
SNDX icon

Legal & General Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Legal & General Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Sell
59,058
-19,178
-25% -$417K ﹤0.01% 2041
2025
Q4 		$1.64M Sell
78,236
-6,310
-7% -$110K ﹤0.01% 2051
2025
Q3 		$1.3M Sell
84,546
-29
-0% -$380 ﹤0.01% 2165
2025
Q2 		$792K Buy
84,575
+3,937
+5% +$43.3K ﹤0.01% 2308
2025
Q1 		$991K Sell
80,638
-224
-0.3% -$3.16K ﹤0.01% 2189
2024
Q4 		$1.07M Sell
80,862
-76
-0.1% -$1.3K ﹤0.01% 2217
2024
Q3 		$1.56M Buy
80,938
+6,513
+9% +$135K ﹤0.01% 2073
2024
Q2 		$1.53M Buy
74,425
+4,647
+7% +$97.3K ﹤0.01% 2062
2024
Q1 		$1.66M Buy
69,778
+14,656
+27% +$327K ﹤0.01% 2005
2023
Q4 		$1.19M Buy
55,122
+4,945
+10% +$76K ﹤0.01% 2152
2023
Q3 		$728K Sell
50,177
-510
-1% -$9.65K ﹤0.01% 2297
2023
Q2 		$1.06M Buy
50,687
+21,679
+75% +$451K ﹤0.01% 2201
2023
Q1 		$613K Buy
29,008
+7,748
+36% +$193K ﹤0.01% 2271
2022
Q4 		$541K Buy
21,260
+2,044
+11% +$47.7K ﹤0.01% 2313
2022
Q3 		$462K Buy
19,216
+1,744
+10% +$39.1K ﹤0.01% 2364
2022
Q2 		$336K Buy
17,472
+4,107
+31% +$68.4K ﹤0.01% 2456
2022
Q1 		$232K Buy
13,365
+872
+7% +$14.7K ﹤0.01% 2620
2021
Q4 		$273K Hold
12,493
– – ﹤0.01% 2593
2021
Q3 		$239K Buy
12,493
+7,450
+148% +$124K ﹤0.01% 2629
2021
Q2 		$87K Sell
5,043
-492
-9% -$9.01K ﹤0.01% 2784
2021
Q1 		$124K Buy
5,535
+1,406
+34% +$31.8K ﹤0.01% 2562
2020
Q4 		$92K Buy
4,129
+807
+24% +$16.7K ﹤0.01% 2609
2020
Q3 		$49K Sell
3,322
-1,124
-25% -$17.1K ﹤0.01% 2703
2020
Q2 		$66K Buy
4,446
+699
+19% +$10.6K ﹤0.01% 2648
2020
Q1 		$41K Sell
3,747
-553
-13% -$5.19K ﹤0.01% 2667
2019
Q4 		$38K Buy
4,300
+787
+22% +$5.78K ﹤0.01% 2929
2019
Q3 		$26K Hold
3,513
– – ﹤0.01% 3037
2019
Q2 		$33K Buy
3,513
+948
+37% +$6.91K ﹤0.01% 2966
2019
Q1 		$13K Hold
2,565
– – ﹤0.01% 3209
2018
Q4 		$11K Hold
2,565
– – ﹤0.01% 3258
2018
Q3 		$21K Hold
2,565
– – ﹤0.01% 3185
2018
Q2 		$18K Buy
2,565
+250
+11% +$2.45K ﹤0.01% 3214
2018
Q1 		$33K Hold
2,315
– – ﹤0.01% 2947
2017
Q4 		$20K Hold
2,315
– – ﹤0.01% 3144
2017
Q3 		$27K Buy
2,315
+1,208
+109% +$14.8K ﹤0.01% 3092
2017
Q2 		$15K Hold
1,107
– – ﹤0.01% 3260
2017
Q1 		$15K Hold
1,107
– – ﹤0.01% 3143
2016
Q4 		$8K Buy
+1,107
New +$12.1K ﹤0.01% 3251

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Legal & General Group's SNDX Position: Q1 2026 in Review

Legal & General Group reduced its Syndax Pharmaceuticals (SNDX) stake by 25% in Q1 2026, selling an estimated $417K and leaving 59,058 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2041.

Legal & General Group first reported a position in SNDX in Q4 2016 and has held it in 38 quarters since. The position peaked at $1.66M in Q1 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Legal & General Group held 59,058 shares of Syndax Pharmaceuticals worth $1.38M as of Q1 2026.
  • Legal & General Group sold 19,178 Syndax Pharmaceuticals shares in Q1 2026, an estimated $417K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2041 holding.
  • Legal & General Group first reported a position in Syndax Pharmaceuticals in Q4 2016 and has held it in 38 quarters since.
  • Legal & General Group's Syndax Pharmaceuticals position peaked at $1.66M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.